In this episode, the team dives headfirst into one of the most volatile, fast-moving conversations in aesthetics today: GLP-1s. With FDA updates signaling the end of compounded options and the market shifting hour by hour, Kevin, Rebekah, and Mitchell discuss what med spas need to know right now—and how CINCH could be the smartest next move.

As Kevin says, “We’re in the Temple of Doom”—everyone’s trying to roll under the closing wall before the opportunity disappears. The team breaks down why GLP-1s became such a lightning rod in aesthetics, how CINCH came to life as a dropship alternative, and why it's more than a workaround—it’s a strategy.

CINCH was created to help med spas stay nimble without sacrificing patient experience or brand integrity. By partnering with a third-party vendor, practices can continue offering medically-backed weight loss solutions without tying up in-clinic resources. And while it runs externally, CINCH is deeply local in intent. The goal? Leverage new patient acquisition to funnel clients back into the med spa for long-term lifetime value.

But this conversation isn’t just about a new tool. It’s about perspective. The team talks candidly about the emotional and business whiplash that comes with GLP-1 volatility and the tough decisions med spa owners are facing. Whether you’re already offering these services or considering it, this episode gives you a grounded, strategic lens on what’s next—and how to ride the wave without getting swept under.